Khosla Ventures
Khosla Ventures is a California-based venture capital firm founded in 2004 by Vinod Khosla. It provides capital and strategic guidance to startups across stages, focusing on technology-driven companies in areas such as artificial intelligence, climate and sustainability, enterprise software and services, fintech, digital health, medical technology and diagnostics, therapeutics, consumer products, and frontier technologies. The firm backs bold ventures with the potential to disrupt markets and improve lives, supporting companies from early to growth stages and working closely with entrepreneurs to apply science, technology and innovative business models. While primarily investing in North American technology companies, Khosla Ventures pursues opportunities globally and emphasizes experimentation and impact alongside financial returns. The firm also maintains related impact initiatives that support entrepreneurs addressing socio-economic challenges in emerging markets.
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in Medical Devices
Aktiia
Series B in 2025
Aktiia develops continuous, convenient, and medical-grade blood pressure monitoring enabled by wearable sensors and machine learning. Built on extensive research, it delivers continuous BP and heart rate data to patients, researchers, and clinicians, supporting personalized insights and new understandings of hypertension. The company aims to make blood pressure management more accessible, accurate, and actionable for people worldwide, addressing a condition that affects over a billion people and causes millions of deaths annually.
Overture Life
Venture Round in 2025
Overture Life, Inc. is a biotechnology company based in New York, established in 2017, that specializes in developing robotic solutions for in vitro fertilization (IVF) applications. The company focuses on automating the IVF process through innovative medical devices and embryo testing methodologies, which enhance the efficiency and success rates of fertility treatments. By optimizing resource use and lowering costs, Overture Life aims to make IVF more accessible to a broader audience. Its technology includes automated cryopreservation and embryo testing services, enabling fertility clinics to identify viable embryos prior to implantation, thereby improving patient outcomes and supporting individuals in their journey to parenthood.
Clear Labs
Series D in 2025
Clear Labs is a biotechnology company specializing in next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. Its platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens, supporting public health initiatives and enhancing safety across various sectors.
Synex Medical
Series A in 2024
Synex Medical is a company focused on advancing health monitoring technology through non-invasive blood testing. It has developed a portable device that utilizes a miniaturized magnetic resonance system to measure blood metabolites without the need for skin penetration. This innovative approach employs only magnets and radio waves, ensuring no adverse health effects for users. By accurately measuring critical metabolites such as glucose, lactate, and ketones, Synex Medical's technology empowers individuals to monitor their health proactively and make informed decisions about their well-being.
Openwater
Venture Round in 2024
Openwater is a medical technology startup founded in 2016 and based in San Francisco, California. The company specializes in developing advanced wearable devices that utilize novel optoelectronics to achieve MRI-like resolution for medical diagnostics and treatments. By employing LCDs with small pixels, Openwater's technology creates holographic images that reduce scattering, enabling physicians to visualize the inner workings of the body and brain at a cellular level. This innovation allows for precise diagnosis and targeted treatment of diseases by manipulating or destroying individual cells without damaging surrounding tissue. Openwater aims to revolutionize medical imaging and improve patient outcomes through its cutting-edge approach.
Aktiia
Series A in 2024
Aktiia develops continuous, convenient, and medical-grade blood pressure monitoring enabled by wearable sensors and machine learning. Built on extensive research, it delivers continuous BP and heart rate data to patients, researchers, and clinicians, supporting personalized insights and new understandings of hypertension. The company aims to make blood pressure management more accessible, accurate, and actionable for people worldwide, addressing a condition that affects over a billion people and causes millions of deaths annually.
TORTUS AI
Seed Round in 2024
TORTUS AI creates and operates an online tool using artificial intelligence for the healthcare industry. It aims to eliminate human error in medicine through clinician co-working with AI. It provides an AI agent for healthcare, a digital worker that can take over all digital tasks from a clinician such as documentation, requesting tests, access and summarizing patient information. Tortus AI was founded in 2022 and is based in London, England.
Vivodyne
Seed Round in 2023
Vivodyne develops an automated robotic system that discovers life-changing drugs and cellular therapies. Its platform cultures human tissues in labs for realistic preclinical drug testing, using advanced AI to accelerate the creation of safe and effective therapeutics.
Forward
Series E in 2023
Forward is a startup focused on transforming healthcare delivery by incorporating advanced technologies that have been underutilized in the industry, such as sensors, mobile applications, and artificial intelligence. Founded in January 2016 by former executives from Google and Uber, Forward operates primary care clinics that emphasize personalized patient care. Through its mobile application and natural language processing system, the company enhances healthcare services, offering features like body scanning, genetic screening, real-time blood testing, and home monitoring of vital signs. These innovations empower patients to take control of their health, promote transparency, and foster better collaboration with their primary care physicians. Backed by prominent investors and entrepreneurs, Forward aims to redefine the patient experience in healthcare.
CellFE
Series A in 2023
CellFE Inc. is a biotechnology company based in San Carlos, California, established in 2017. It specializes in the development of a microfluidics-based device designed to deliver gene-editing molecules into human cells. This innovative platform enhances the manufacturing and development of cell therapies by utilizing rapid cell compression techniques that facilitate the uptake of therapeutic molecules from surrounding fluids. By enabling the transport of hard-to-deliver molecules, CellFE aims to improve the effectiveness of treatments for various disorders, supporting medical researchers in their efforts to advance patient care and outcomes.
Rejuvenation Technologies
Seed Round in 2023
Founded in 2016, Rejuvenation Technologies is a biotechnology company based in Mountain View, California. It specializes in developing nucleoside-modified TERT mRNA to safely extend telomeres for human health extension.
SiPhox Health
Seed Round in 2023
SiPhox Health, based in Cambridge, Massachusetts, specializes in designing and manufacturing innovative diagnostic solutions. The company develops next-generation diagnostics infrastructure, including at-home test kits and central lab systems. Their flagship product is a disposable biosensor cartridge that assesses 17 blood biomarkers, providing insights into inflammation, hormonal health, metabolic fitness, and cardiovascular health. SiPhox Health's platform merges biochemistry, photonic chip technology, integrated photonics, electronics, and microfluidics to enable sensitive readouts of immunoassays and nucleic acid tests, facilitating point-of-need and at-home diagnostics.
SiPhox Health
Series A in 2023
SiPhox Health, based in Cambridge, Massachusetts, specializes in designing and manufacturing innovative diagnostic solutions. The company develops next-generation diagnostics infrastructure, including at-home test kits and central lab systems. Their flagship product is a disposable biosensor cartridge that assesses 17 blood biomarkers, providing insights into inflammation, hormonal health, metabolic fitness, and cardiovascular health. SiPhox Health's platform merges biochemistry, photonic chip technology, integrated photonics, electronics, and microfluidics to enable sensitive readouts of immunoassays and nucleic acid tests, facilitating point-of-need and at-home diagnostics.
TORTUS AI
Seed Round in 2023
TORTUS AI creates and operates an online tool using artificial intelligence for the healthcare industry. It aims to eliminate human error in medicine through clinician co-working with AI. It provides an AI agent for healthcare, a digital worker that can take over all digital tasks from a clinician such as documentation, requesting tests, access and summarizing patient information. Tortus AI was founded in 2022 and is based in London, England.
Tachyon Therapeutics
Series A in 2023
Tachyon Therapeutics develops innovative compounds to enhance cancer treatments. It is currently conducting Phase 1 clinical trials to evaluate the safety and efficacy of its lead compound, TACH101.
Synchron
Series C in 2022
Synchron is a company that develops implantable neural interfaces designed to restore motor function by recording and interpreting brain activity through minimally invasive devices. Its catheter-delivered brain implants record neuron signals and translate them into control signals for prosthetics or digital devices, enabling users with motor impairments to interact with technology through thought. The devices incorporate electrode arrays within a stent-like platform to create a brain-computer interface that modulates neural activity in targeted brain regions. The goal is to provide a less invasive option for patients to regain voluntary control over assistive technologies, augmenting mobility and communication for those with paralysis or severe motor limitation.
Ultima Genomics
Venture Round in 2022
Ultima Genomics is a biotechnology company established in 2016 and headquartered in Newark, California. It specializes in genome-scale sequencing technology, focusing on providing analytical services to various enterprises. By employing an open substrate, Ultima Genomics creates a vast, low-cost reaction surface that facilitates billions of reads without relying on expensive flow cells or complex fluidic systems. The company utilizes specialized sequencing hardware combined with machine learning techniques to ensure reproducible and accurate results. This innovative approach enables clients to obtain genomic reports at scale, enhancing the speed and efficiency of sequencing while significantly reducing costs. Ultima Genomics aims to harness the potential of genomic information to drive advancements in biology and improve human health.
Mirvie
Series B in 2022
Mirvie is a biotechnology company specializing in precise, non-invasive diagnostic tests for maternal-fetal health. Founded in 2018, the company aims to enhance pregnancy safety by providing actionable insights to families and enabling early intervention for potential complications.
Vicarious Surgical
Post in 2021
Vicarious Surgical Inc. is a robotics company based in Charlestown, Massachusetts, established in 2014. The company specializes in developing advanced technologies for minimally invasive surgical procedures, focusing on enhancing surgical efficiency, improving patient outcomes, and reducing healthcare costs. Its flagship product, the Vicarious Surgical Robotic System, integrates virtual reality software with human-like robotic capabilities, enabling surgeons to perform complex surgeries with greater precision and control. Designed for abdominal access through a single port, the system is compact and portable, facilitating easy integration into existing operating rooms. By minimizing invasiveness, Vicarious Surgical aims to accelerate patient recovery times and decrease post-operative discomfort, thereby transforming the landscape of surgical care.
Synchron
Series B in 2021
Synchron is a company that develops implantable neural interfaces designed to restore motor function by recording and interpreting brain activity through minimally invasive devices. Its catheter-delivered brain implants record neuron signals and translate them into control signals for prosthetics or digital devices, enabling users with motor impairments to interact with technology through thought. The devices incorporate electrode arrays within a stent-like platform to create a brain-computer interface that modulates neural activity in targeted brain regions. The goal is to provide a less invasive option for patients to regain voluntary control over assistive technologies, augmenting mobility and communication for those with paralysis or severe motor limitation.
Clear Labs
Series C in 2021
Clear Labs is a biotechnology company specializing in next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. Its platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens, supporting public health initiatives and enhancing safety across various sectors.
Hello Heart
Series C in 2021
Hello Heart Inc., established in 2013 and headquartered in Redwood City, California, specializes in developing digital health solutions. Its flagship product is Hello Heart, a mobile application designed to empower individuals to manage their heart health effectively. The app enables users to track their blood pressure and weight, providing real-time personalized tips based on clinical guidelines. Employers can also utilize this platform to proactively manage employee health risks associated with high blood pressure, fostering behavior change and preventing serious health issues.
Overture Life
Series B in 2021
Overture Life, Inc. is a biotechnology company based in New York, established in 2017, that specializes in developing robotic solutions for in vitro fertilization (IVF) applications. The company focuses on automating the IVF process through innovative medical devices and embryo testing methodologies, which enhance the efficiency and success rates of fertility treatments. By optimizing resource use and lowering costs, Overture Life aims to make IVF more accessible to a broader audience. Its technology includes automated cryopreservation and embryo testing services, enabling fertility clinics to identify viable embryos prior to implantation, thereby improving patient outcomes and supporting individuals in their journey to parenthood.
Docbot
Series A in 2021
DocBot, Inc. is an artificial intelligence technology company based in Irvine, California, specializing in gastrointestinal diseases. The company develops web-based applications for iOS and Android devices that serve as a clinical decision support system, aggregating patient information and providing cloud analytics to healthcare professionals. Its flagship product is built on the UltivisionAI software platform, which offers real-time image analysis, automated reporting, and analytical tools aimed at enhancing patient care and clinical workflows. By integrating various data sources from imaging systems to pathology requisitions, DocBot's platform aids physicians in detecting colorectal cancer and other gastrointestinal conditions, ultimately striving to improve healthcare outcomes and reduce patient risks.
Apton Biosystems
Series A in 2021
Apton Biosystems, Inc. is a biotechnology company based in Pleasanton, California, founded in 2012. The company specializes in developing advanced optical systems for sequencing and protein detection, utilizing super-resolution technology to analyze molecules that are spaced closer than the wavelength of light. This innovative approach facilitates multi-omic sequencing and single-molecule protein detection, significantly enhancing capabilities in biomarker discovery, early disease detection, and therapeutic monitoring. Apton Biosystems aims to advance preventive health and precision medicine by addressing spatial challenges in high-density sequencing and protein analysis, thus contributing to improved healthcare outcomes.
StimScience
Seed Round in 2021
StimScience develops non-invasive brain stimulation technologies, including transcranial direct current stimulation, transcranial alternating current stimulation, and transcranial random noise stimulation. Its NeuroMod tXES platform enables users to generate arbitrary waveforms for tailored tES applications. Founded in 2017 and based in Berkeley, California, StimScience focuses on commercializing neuroscience and sleep research into products and services for individuals, employers, and health plans. The team comprises leading sleep and neuroscience researchers and advisors, with early funding supporting the launch of Somnee, an advanced diagnostic and therapeutic product designed to help people fall asleep faster and achieve higher-quality restorative sleep. Sleep health is central to mental health, memory, learning, and physical well-being.
Rightway
Series C in 2021
Rightway is a technology-driven healthcare company that focuses on care navigation and pharmacy benefit management. It offers a platform and services that guide members to appropriate care and therapies, with dedicated clinical guides and personalized support. By providing transparent pharmacy benefits and decision support, Rightway aims to help healthcare organizations reduce total cost of care while improving member engagement and access to high-value care. The company's platform reimagines the member experience by simplifying interactions, enhancing visibility into benefits, and facilitating more informed choices. Through its care navigation and PBM solutions, Rightway seeks to lower healthcare spending for clients and members by directing them to optimal care pathways and cost-effective treatments. The business combines technology with clinical guidance to streamline benefits administration, support member decision making, and drive better health outcomes.
Forward
Series D in 2021
Forward is a startup focused on transforming healthcare delivery by incorporating advanced technologies that have been underutilized in the industry, such as sensors, mobile applications, and artificial intelligence. Founded in January 2016 by former executives from Google and Uber, Forward operates primary care clinics that emphasize personalized patient care. Through its mobile application and natural language processing system, the company enhances healthcare services, offering features like body scanning, genetic screening, real-time blood testing, and home monitoring of vital signs. These innovations empower patients to take control of their health, promote transparency, and foster better collaboration with their primary care physicians. Backed by prominent investors and entrepreneurs, Forward aims to redefine the patient experience in healthcare.
Earli
Series A in 2021
Earli is a biotechnology company focused on advancing cancer detection and treatment through innovative technology. The company specializes in developing devices that utilize a novel gene therapy approach known as Synthetic Biopsy. This method compels cancer cells to produce synthetic biomarkers, which are not naturally occurring in the human body. These biomarkers can then be detected in bodily fluids such as blood, urine, or breath, allowing for early identification of cancer. By facilitating the early detection of homogeneous tumors, Earli aims to significantly improve the chances of successful treatment and personalize therapy options for patients. Additionally, the technology is designed to be visible during imaging procedures such as PET scans, enhancing the monitoring of cancer progression and treatment efficacy.
Advanced Chemotherapy Technologies
Series A in 2020
Advanced Chemotherapy Technologies is a healthcare company that is developing breakthrough combination drug-device technologies for treating pancreatic cancer.
Invoy
Series A in 2020
Invoy is a company focused on enhancing health and weight loss outcomes through the integration of science, data, and artificial intelligence. It develops a monitoring medical device that offers personalized nutrition and wellness services by generating real-time data on an individual's metabolism. This device not only provides tailored, predictive nutrition recommendations but also features affordable breath analyzers for medical applications. By addressing the unique body chemistry of each individual, Invoy aims to empower users to achieve their specific health and wellness objectives.
SiPhox Health
Seed Round in 2020
SiPhox Health, based in Cambridge, Massachusetts, specializes in designing and manufacturing innovative diagnostic solutions. The company develops next-generation diagnostics infrastructure, including at-home test kits and central lab systems. Their flagship product is a disposable biosensor cartridge that assesses 17 blood biomarkers, providing insights into inflammation, hormonal health, metabolic fitness, and cardiovascular health. SiPhox Health's platform merges biochemistry, photonic chip technology, integrated photonics, electronics, and microfluidics to enable sensitive readouts of immunoassays and nucleic acid tests, facilitating point-of-need and at-home diagnostics.
Vicarious Surgical
Series A in 2020
Vicarious Surgical Inc. is a robotics company based in Charlestown, Massachusetts, established in 2014. The company specializes in developing advanced technologies for minimally invasive surgical procedures, focusing on enhancing surgical efficiency, improving patient outcomes, and reducing healthcare costs. Its flagship product, the Vicarious Surgical Robotic System, integrates virtual reality software with human-like robotic capabilities, enabling surgeons to perform complex surgeries with greater precision and control. Designed for abdominal access through a single port, the system is compact and portable, facilitating easy integration into existing operating rooms. By minimizing invasiveness, Vicarious Surgical aims to accelerate patient recovery times and decrease post-operative discomfort, thereby transforming the landscape of surgical care.
Caption Health
Series B in 2020
Caption Health, Inc. is a technology company specializing in artificial intelligence software designed to enhance the acquisition and interpretation of ultrasound exams. Its flagship product, Caption AI, serves as an AI-guided medical imaging acquisition system that assists healthcare providers by offering real-time guidance, automating quality assessments, and interpreting ultrasound images to ensure diagnostic accuracy. Founded in 2013 and headquartered in Brisbane, California, Caption Health was previously known as Bay Labs, Inc. The company aims to scale its commercial operations and further develop its AI technology platform, intending to broaden the application of Caption AI across various clinical settings as adoption increases among healthcare practitioners.
Kernel
Series C in 2020
Kernel, a neuroscience company founded in 2016 and headquartered in Los Angeles, California, develops advanced brain-recording technologies aimed at enhancing human cognition. The company specializes in creating a non-invasive brain interface that captures neural signals with quality comparable to traditional imaging methods like fMRI and MEG, while being as user-friendly as EEG. Kernel's primary focus is on addressing dysfunctions linked to neurodegenerative diseases, offering neuroprosthetics that can mimic, repair, and improve cognitive functions. Additionally, the company provides access to brain imaging devices that enable remote experimentation, thereby furthering the understanding and treatment of neurological disorders.
Siren Care
Series B in 2020
Siren Care develops wearable health technology for diabetic foot health monitoring. The company offers Siren diabetic socks and a foot temperature monitoring system that continuously tracks foot temperature to detect early signs of inflammation and diabetic foot ulcers, helping prevent complications such as amputations. Data from the socks can be accessed via a mobile application and shared with providers, including podiatrists, to support monitoring and timely intervention. It serves patients and healthcare providers through its flagship Siren Diabetic Foot Program. Founded in 2015 and based in San Francisco, Siren Care focuses on proactive foot health management for individuals at risk of diabetic foot complications.
Clear Labs
Venture Round in 2020
Clear Labs is a biotechnology company specializing in next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. Its platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens, supporting public health initiatives and enhancing safety across various sectors.
HeartVista
Series A in 2020
HeartVista is a medical technology company that provides one-click diagnostic imaging. It brought in machine learning to make the scanning process faster, easier, and more consistent. Its platform leverages existing scanners and contains all of the mri tools needed for a comprehensive cardiac examination, with just one click.
Genalyte
Series C in 2020
Genalyte, Inc. is a clinical and diagnostic life sciences company based in San Diego, California, that specializes in rapid diagnostic testing solutions for healthcare providers, patients, and researchers. Founded in 2007, Genalyte has developed a unique technology platform employing silicon photonic biosensors to quantify the interactions between biomolecules, such as antibodies and proteins. This innovative approach allows for the direct measurement of protein binding and nucleic acid hybridization, facilitating the monitoring of autoimmune diseases, cancer biomarker screening, and the detection of infectious agents, including Ebola. The company's Maverick platform enables rapid testing in various healthcare settings, with results typically available in under thirty minutes, thereby enhancing patient care and improving resource efficiency within the healthcare system.
Hello Heart
Series B in 2019
Hello Heart Inc., established in 2013 and headquartered in Redwood City, California, specializes in developing digital health solutions. Its flagship product is Hello Heart, a mobile application designed to empower individuals to manage their heart health effectively. The app enables users to track their blood pressure and weight, providing real-time personalized tips based on clinical guidelines. Employers can also utilize this platform to proactively manage employee health risks associated with high blood pressure, fostering behavior change and preventing serious health issues.
Overture Life
Venture Round in 2019
Overture Life, Inc. is a biotechnology company based in New York, established in 2017, that specializes in developing robotic solutions for in vitro fertilization (IVF) applications. The company focuses on automating the IVF process through innovative medical devices and embryo testing methodologies, which enhance the efficiency and success rates of fertility treatments. By optimizing resource use and lowering costs, Overture Life aims to make IVF more accessible to a broader audience. Its technology includes automated cryopreservation and embryo testing services, enabling fertility clinics to identify viable embryos prior to implantation, thereby improving patient outcomes and supporting individuals in their journey to parenthood.
Neurotrack
Series C in 2019
Neurotrack is a digital health company focused on the early detection and management of Alzheimer's disease and other dementias. It offers turnkey cognitive assessment platforms for providers to facilitate rapid, patient-guided screening and ongoing monitoring of cognitive function, usable in clinic or at home to fit diverse workflows. The platform employs eye-tracking technology and culturally-agnostic symbols to deliver rapid assessments with instant, objective scoring integrated with electronic health records, and supports remote and in-clinic administration, ongoing monitoring tools, and educational resources addressing modifiable risk factors. Neurotrack has published peer-reviewed research, holds patents on its proprietary technology, and has FDA Class II medical device status. Founded in 2012 and based in Redwood City, California.
Docbot
Seed Round in 2019
DocBot, Inc. is an artificial intelligence technology company based in Irvine, California, specializing in gastrointestinal diseases. The company develops web-based applications for iOS and Android devices that serve as a clinical decision support system, aggregating patient information and providing cloud analytics to healthcare professionals. Its flagship product is built on the UltivisionAI software platform, which offers real-time image analysis, automated reporting, and analytical tools aimed at enhancing patient care and clinical workflows. By integrating various data sources from imaging systems to pathology requisitions, DocBot's platform aids physicians in detecting colorectal cancer and other gastrointestinal conditions, ultimately striving to improve healthcare outcomes and reduce patient risks.
Vicarious Surgical
Series B in 2019
Vicarious Surgical Inc. is a robotics company based in Charlestown, Massachusetts, established in 2014. The company specializes in developing advanced technologies for minimally invasive surgical procedures, focusing on enhancing surgical efficiency, improving patient outcomes, and reducing healthcare costs. Its flagship product, the Vicarious Surgical Robotic System, integrates virtual reality software with human-like robotic capabilities, enabling surgeons to perform complex surgeries with greater precision and control. Designed for abdominal access through a single port, the system is compact and portable, facilitating easy integration into existing operating rooms. By minimizing invasiveness, Vicarious Surgical aims to accelerate patient recovery times and decrease post-operative discomfort, thereby transforming the landscape of surgical care.
StimScience
Seed Round in 2019
StimScience develops non-invasive brain stimulation technologies, including transcranial direct current stimulation, transcranial alternating current stimulation, and transcranial random noise stimulation. Its NeuroMod tXES platform enables users to generate arbitrary waveforms for tailored tES applications. Founded in 2017 and based in Berkeley, California, StimScience focuses on commercializing neuroscience and sleep research into products and services for individuals, employers, and health plans. The team comprises leading sleep and neuroscience researchers and advisors, with early funding supporting the launch of Somnee, an advanced diagnostic and therapeutic product designed to help people fall asleep faster and achieve higher-quality restorative sleep. Sleep health is central to mental health, memory, learning, and physical well-being.
Siren Care
Series A in 2018
Siren Care develops wearable health technology for diabetic foot health monitoring. The company offers Siren diabetic socks and a foot temperature monitoring system that continuously tracks foot temperature to detect early signs of inflammation and diabetic foot ulcers, helping prevent complications such as amputations. Data from the socks can be accessed via a mobile application and shared with providers, including podiatrists, to support monitoring and timely intervention. It serves patients and healthcare providers through its flagship Siren Diabetic Foot Program. Founded in 2015 and based in San Francisco, Siren Care focuses on proactive foot health management for individuals at risk of diabetic foot complications.
Clear Labs
Series B in 2018
Clear Labs is a biotechnology company specializing in next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. Its platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens, supporting public health initiatives and enhancing safety across various sectors.
Eva
Venture Round in 2018
Higia Technologies, founded in 2016 and based in Mexico City, specializes in developing EVA, a non-invasive wearable device aimed at assessing breast cancer risk. This innovative device features tactile sensors that map the surface of the breast and its surrounding areas. By continuously monitoring changes in breast temperature, size, and weight through embedded biosensors, EVA empowers women to actively track their breast health. The company's focus is on making breast cancer risk assessment more accessible and user-friendly.
Openwater
Seed Round in 2018
Openwater is a medical technology startup founded in 2016 and based in San Francisco, California. The company specializes in developing advanced wearable devices that utilize novel optoelectronics to achieve MRI-like resolution for medical diagnostics and treatments. By employing LCDs with small pixels, Openwater's technology creates holographic images that reduce scattering, enabling physicians to visualize the inner workings of the body and brain at a cellular level. This innovation allows for precise diagnosis and targeted treatment of diseases by manipulating or destroying individual cells without damaging surrounding tissue. Openwater aims to revolutionize medical imaging and improve patient outcomes through its cutting-edge approach.
Zebra Medical Vision
Series C in 2018
Zebra Medical Vision is an Israel-based company that develops an imaging analytics platform for healthcare. The platform supplies clinicians with imaging research tools, provides advanced learning and computer-vision diagnostic algorithms for developers, and offers risk management and preventative care tools for providers. The company also offers researchers access to tools and datasets to accelerate the development of decision-support and diagnostic technologies. Founded in 2014 and headquartered in Shefayim, Zebra Medical Vision collaborates with partners such as USARAD Holdings and TELUS Ventures and has deployed its AI-enabled imaging analytics across hospitals worldwide.
Vicarious Surgical
Series A in 2018
Vicarious Surgical Inc. is a robotics company based in Charlestown, Massachusetts, established in 2014. The company specializes in developing advanced technologies for minimally invasive surgical procedures, focusing on enhancing surgical efficiency, improving patient outcomes, and reducing healthcare costs. Its flagship product, the Vicarious Surgical Robotic System, integrates virtual reality software with human-like robotic capabilities, enabling surgeons to perform complex surgeries with greater precision and control. Designed for abdominal access through a single port, the system is compact and portable, facilitating easy integration into existing operating rooms. By minimizing invasiveness, Vicarious Surgical aims to accelerate patient recovery times and decrease post-operative discomfort, thereby transforming the landscape of surgical care.
Siren Care
Seed Round in 2018
Siren Care develops wearable health technology for diabetic foot health monitoring. The company offers Siren diabetic socks and a foot temperature monitoring system that continuously tracks foot temperature to detect early signs of inflammation and diabetic foot ulcers, helping prevent complications such as amputations. Data from the socks can be accessed via a mobile application and shared with providers, including podiatrists, to support monitoring and timely intervention. It serves patients and healthcare providers through its flagship Siren Diabetic Foot Program. Founded in 2015 and based in San Francisco, Siren Care focuses on proactive foot health management for individuals at risk of diabetic foot complications.
Neurotrack
Series B in 2018
Neurotrack is a digital health company focused on the early detection and management of Alzheimer's disease and other dementias. It offers turnkey cognitive assessment platforms for providers to facilitate rapid, patient-guided screening and ongoing monitoring of cognitive function, usable in clinic or at home to fit diverse workflows. The platform employs eye-tracking technology and culturally-agnostic symbols to deliver rapid assessments with instant, objective scoring integrated with electronic health records, and supports remote and in-clinic administration, ongoing monitoring tools, and educational resources addressing modifiable risk factors. Neurotrack has published peer-reviewed research, holds patents on its proprietary technology, and has FDA Class II medical device status. Founded in 2012 and based in Redwood City, California.
Mirvie
Series A in 2018
Mirvie is a biotechnology company specializing in precise, non-invasive diagnostic tests for maternal-fetal health. Founded in 2018, the company aims to enhance pregnancy safety by providing actionable insights to families and enabling early intervention for potential complications.
Ontera
Series A in 2017
Ontera develops handheld diagnostic platforms using silicon nanopore chips and proprietary biochemistry. These platforms detect and differentiate single molecules in DNA, RNA, proteins, viruses, antibodies, and other analytes from various life forms. Applications include human and animal diagnostics, agriculture, food safety testing, environmental monitoring, and more.
Syllable
Seed Round in 2017
Syllable is a technology company that develops a platform designed to enhance communication between patients and healthcare providers through text and voice interactions. The platform enables patients to access vital healthcare information regarding primary care, specialty referrals, vaccinations, and general practice, facilitating guidance outside of traditional clinical settings. Additionally, Syllable focuses on building AI agents and managing AI operations, integrating tools and services from third-party providers of large language models and AI technologies, which further supports its mission to improve patient-provider communication.
Clear Labs
Series B in 2016
Clear Labs is a biotechnology company specializing in next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. Its platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens, supporting public health initiatives and enhancing safety across various sectors.
Caption Health
Series A in 2016
Caption Health, Inc. is a technology company specializing in artificial intelligence software designed to enhance the acquisition and interpretation of ultrasound exams. Its flagship product, Caption AI, serves as an AI-guided medical imaging acquisition system that assists healthcare providers by offering real-time guidance, automating quality assessments, and interpreting ultrasound images to ensure diagnostic accuracy. Founded in 2013 and headquartered in Brisbane, California, Caption Health was previously known as Bay Labs, Inc. The company aims to scale its commercial operations and further develop its AI technology platform, intending to broaden the application of Caption AI across various clinical settings as adoption increases among healthcare practitioners.
Genalyte
Series D in 2016
Genalyte, Inc. is a clinical and diagnostic life sciences company based in San Diego, California, that specializes in rapid diagnostic testing solutions for healthcare providers, patients, and researchers. Founded in 2007, Genalyte has developed a unique technology platform employing silicon photonic biosensors to quantify the interactions between biomolecules, such as antibodies and proteins. This innovative approach allows for the direct measurement of protein binding and nucleic acid hybridization, facilitating the monitoring of autoimmune diseases, cancer biomarker screening, and the detection of infectious agents, including Ebola. The company's Maverick platform enables rapid testing in various healthcare settings, with results typically available in under thirty minutes, thereby enhancing patient care and improving resource efficiency within the healthcare system.
Vicarious Surgical
Venture Round in 2016
Vicarious Surgical Inc. is a robotics company based in Charlestown, Massachusetts, established in 2014. The company specializes in developing advanced technologies for minimally invasive surgical procedures, focusing on enhancing surgical efficiency, improving patient outcomes, and reducing healthcare costs. Its flagship product, the Vicarious Surgical Robotic System, integrates virtual reality software with human-like robotic capabilities, enabling surgeons to perform complex surgeries with greater precision and control. Designed for abdominal access through a single port, the system is compact and portable, facilitating easy integration into existing operating rooms. By minimizing invasiveness, Vicarious Surgical aims to accelerate patient recovery times and decrease post-operative discomfort, thereby transforming the landscape of surgical care.
Color
Series B in 2016
Color is a healthcare technology company that offers a comprehensive platform for population health management, facilitating equitable and accessible healthcare delivery. The company specializes in large-scale health initiatives, providing solutions that include population genomics programs and high-throughput testing services, such as those for COVID-19. By centralizing essential healthcare capabilities, Color enables businesses, schools, and state public health departments to implement effective preventive health programs, regardless of the geographical distribution of their populations. Its innovative approach addresses various healthcare logistics challenges, streamlining processes related to testing, screening, treatment, and referrals, while creating diverse market opportunities and revenue streams for clinical teams.
Forward
Seed Round in 2016
Forward is a startup focused on transforming healthcare delivery by incorporating advanced technologies that have been underutilized in the industry, such as sensors, mobile applications, and artificial intelligence. Founded in January 2016 by former executives from Google and Uber, Forward operates primary care clinics that emphasize personalized patient care. Through its mobile application and natural language processing system, the company enhances healthcare services, offering features like body scanning, genetic screening, real-time blood testing, and home monitoring of vital signs. These innovations empower patients to take control of their health, promote transparency, and foster better collaboration with their primary care physicians. Backed by prominent investors and entrepreneurs, Forward aims to redefine the patient experience in healthcare.
Zebra Medical Vision
Series B in 2016
Zebra Medical Vision is an Israel-based company that develops an imaging analytics platform for healthcare. The platform supplies clinicians with imaging research tools, provides advanced learning and computer-vision diagnostic algorithms for developers, and offers risk management and preventative care tools for providers. The company also offers researchers access to tools and datasets to accelerate the development of decision-support and diagnostic technologies. Founded in 2014 and headquartered in Shefayim, Zebra Medical Vision collaborates with partners such as USARAD Holdings and TELUS Ventures and has deployed its AI-enabled imaging analytics across hospitals worldwide.
Neurotrack
Series A in 2016
Neurotrack is a digital health company focused on the early detection and management of Alzheimer's disease and other dementias. It offers turnkey cognitive assessment platforms for providers to facilitate rapid, patient-guided screening and ongoing monitoring of cognitive function, usable in clinic or at home to fit diverse workflows. The platform employs eye-tracking technology and culturally-agnostic symbols to deliver rapid assessments with instant, objective scoring integrated with electronic health records, and supports remote and in-clinic administration, ongoing monitoring tools, and educational resources addressing modifiable risk factors. Neurotrack has published peer-reviewed research, holds patents on its proprietary technology, and has FDA Class II medical device status. Founded in 2012 and based in Redwood City, California.
Clear Labs
Series A in 2015
Clear Labs is a biotechnology company specializing in next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. Its platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens, supporting public health initiatives and enhancing safety across various sectors.
Genalyte
Series C in 2015
Genalyte, Inc. is a clinical and diagnostic life sciences company based in San Diego, California, that specializes in rapid diagnostic testing solutions for healthcare providers, patients, and researchers. Founded in 2007, Genalyte has developed a unique technology platform employing silicon photonic biosensors to quantify the interactions between biomolecules, such as antibodies and proteins. This innovative approach allows for the direct measurement of protein binding and nucleic acid hybridization, facilitating the monitoring of autoimmune diseases, cancer biomarker screening, and the detection of infectious agents, including Ebola. The company's Maverick platform enables rapid testing in various healthcare settings, with results typically available in under thirty minutes, thereby enhancing patient care and improving resource efficiency within the healthcare system.
Klarismo
Seed Round in 2015
Klarismo Limited is a health technology company based in London, United Kingdom, that specializes in 3D body analysis using magnetic resonance imaging (MRI). Founded in 2014, it offers a platform that converts full-body MRI scans into detailed 3D virtual models, allowing users to explore their body composition with unprecedented precision. The service provides volumetric measurements of muscle and fat tissues, helping health-conscious consumers and amateur athletes understand their physiological changes over time. With regular MRI scans, Klarismo updates users' 3D models to reflect changes in muscle and fat distribution, facilitating effective monitoring of fitness and dietary progress. In addition to serving individual users, the company assists private medical imaging centers in optimizing their resources and builds a database of full-body MRI scans for medical research purposes.
Color
Series A in 2015
Color is a healthcare technology company that offers a comprehensive platform for population health management, facilitating equitable and accessible healthcare delivery. The company specializes in large-scale health initiatives, providing solutions that include population genomics programs and high-throughput testing services, such as those for COVID-19. By centralizing essential healthcare capabilities, Color enables businesses, schools, and state public health departments to implement effective preventive health programs, regardless of the geographical distribution of their populations. Its innovative approach addresses various healthcare logistics challenges, streamlining processes related to testing, screening, treatment, and referrals, while creating diverse market opportunities and revenue streams for clinical teams.
Zebra Medical Vision
Seed Round in 2015
Zebra Medical Vision is an Israel-based company that develops an imaging analytics platform for healthcare. The platform supplies clinicians with imaging research tools, provides advanced learning and computer-vision diagnostic algorithms for developers, and offers risk management and preventative care tools for providers. The company also offers researchers access to tools and datasets to accelerate the development of decision-support and diagnostic technologies. Founded in 2014 and headquartered in Shefayim, Zebra Medical Vision collaborates with partners such as USARAD Holdings and TELUS Ventures and has deployed its AI-enabled imaging analytics across hospitals worldwide.
Apton Biosystems
Venture Round in 2015
Apton Biosystems, Inc. is a biotechnology company based in Pleasanton, California, founded in 2012. The company specializes in developing advanced optical systems for sequencing and protein detection, utilizing super-resolution technology to analyze molecules that are spaced closer than the wavelength of light. This innovative approach facilitates multi-omic sequencing and single-molecule protein detection, significantly enhancing capabilities in biomarker discovery, early disease detection, and therapeutic monitoring. Apton Biosystems aims to advance preventive health and precision medicine by addressing spatial challenges in high-density sequencing and protein analysis, thus contributing to improved healthcare outcomes.
Caption Health
Seed Round in 2015
Caption Health, Inc. is a technology company specializing in artificial intelligence software designed to enhance the acquisition and interpretation of ultrasound exams. Its flagship product, Caption AI, serves as an AI-guided medical imaging acquisition system that assists healthcare providers by offering real-time guidance, automating quality assessments, and interpreting ultrasound images to ensure diagnostic accuracy. Founded in 2013 and headquartered in Brisbane, California, Caption Health was previously known as Bay Labs, Inc. The company aims to scale its commercial operations and further develop its AI technology platform, intending to broaden the application of Caption AI across various clinical settings as adoption increases among healthcare practitioners.
Embrace Global
Series A in 2013
Embrace Innovations is a Bengaluru-based healthcare technology company focused on developing innovative and affordable medical devices for emerging markets. The company specializes in creating solutions to improve maternal and child health, notably through its flagship product, the Embrace Nest, a portable infant warmer designed for low birth-weight and premature babies. This device offers a cost-effective alternative to conventional incubators, priced at less than 1% of typical incubator solutions, aiming to reduce the high mortality rate among premature infants. In addition to its existing products, Embrace conducts research and development to foster new low-cost healthcare innovations, addressing critical needs in underserved communities.
CellScope
Seed Round in 2012
CellScope, Inc. is a technology company that specializes in developing microscopic imaging devices for at-home disease diagnosis, utilizing smartphone cameras linked to a web platform. Founded in 2010 and based in Menlo Park, California, CellScope offers a range of products, including a mobile otoscope that allows pediatricians to maintain a visual history of patients' middle ear conditions, and a mobile dermascope that enables patients to capture and send high-magnification images of their skin. Their innovative smartphone-enabled otoscope facilitates remote diagnosis of pediatric ear infections, enhancing telemedicine capabilities. By providing clinicians with tools to share images and videos with patients and track medical conditions over time, CellScope's technology improves remote diagnosis, promotes ear and skin health, and reduces the need for unnecessary antibiotics, thereby saving time and resources in healthcare.
HeartVista
Seed Round in 2012
HeartVista is a medical technology company that provides one-click diagnostic imaging. It brought in machine learning to make the scanning process faster, easier, and more consistent. Its platform leverages existing scanners and contains all of the mri tools needed for a comprehensive cardiac examination, with just one click.
Vivodyne
Vivodyne develops an automated robotic system that discovers life-changing drugs and cellular therapies. Its platform cultures human tissues in labs for realistic preclinical drug testing, using advanced AI to accelerate the creation of safe and effective therapeutics.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.